
    due to enrollment challenges
  
['peripheral t-cell lymphoma (ptcl)', 'cutaneous t-cell lymphoma (ctcl)']
['selinexor']

        Inclusion Criteria:

          -  ECOG performance status of ≤2.

          -  Relapsed or refractory disease to at least one prior systemic regimen.

          -  Measurable disease: according to International Working Group (IWG) guidelines for all
             patients with PTCL and according to CTCL Response in Skin consensus criteria for all
             patients with CTCL.

          -  Objective, documented evidence of disease progression on study entry.

        Exclusion Criteria:

          -  Known active central nervous system (CNS) lymphoma.

          -  Active graft-versus-host disease after allogeneic stem cell transplantation. At least
             4 months must have elapsed since completion of allogeneic stem cell transplantation.

          -  Unable to swallow tablets or malabsorption syndrome, disease significantly affecting
             gastrointestinal function.
      